

Ordering Physician Signature (REQUIRED) $_$

Division of Pathology

3333 Burnet Avenue, MGPS Lab, R2.001 Cincinnati, OH 45229

Phone: 513-636-9820 • Fax: 513-517-7099

pathology@cchmc.org • cincinnatichildrens.org/pathology

MOLECULAR AND GENOMIC PATHOLOGY SERVICES - ONCOLOGY

All Information Must Be Completed Before Sa	mple Can Be Processed. Please Type or Print.
PATIENT INFORMATION	ORDERING PHYSICIAN INFORMATION
Patient Name:,,	Office/ Practice/ Institution Name:
Address:	Ordering Physician:
Home Phone:	Street Address:
MR# Date of Birth /	City:
Gender: ☐ Male ☐ Female	State:Postal Code:Country: Phone:Fax:
CLINICAL HISTORY	Email Address:
Clinical History:	BILLING INFORMATION
	REFERRING INSTITUTION
	Institution:
ICD-10 Code:	Address:
SAMPLE/SPECIMEN INFORMATION	City/State/Zip:
Specimen Type: FFPE tissue (paraffin block, or 1 H&E plus 6 unstained slides)** Peripheral blood Bone marrow	Accounts Payable Contact Name: Phone: Fax:
Collection Date/Time:	Email:
Phone # for questions: FedEx account number*:	*** Please note, we DO NOT bill the patient or their insurance unless they are transferring care to Cincinnati Children's. ***
*For tissue block. If not provided, blocks will be returned via regular mail.	TEST(S) REQUESTED
Please ship materials to:	**For tests ordered on formalin-fixed, paraffin-embedded tissue, the molecular pathologist or laboratory director will review histologic material for adequacy and appropriate test indication.
Cincinnati Children's Hospital Medical Center Attn: Molecular and Genomic Pathology Services (MGPS) 3333 Burnet Avenue, R2.001 Cincinnati, OH 45229-3039	A final or preliminary surgical pathology or cytopathology report must accompany the test requisition.** HistioTrak Used for monitoring the disease burden of patients with histiocytosis
Note: Please see test information sheet for acceptable specimen type, collection container, and volume.	that harbor a BRAF V600E mutation, during or after therapy. In this setting, it is NOT a diagnostic test. Prior BRAF V600E mutation status should be known before performing the test. In select instances, HistioTrak testing can be used to determine BRAF V600E mutation status on tissue (FFPE) specimens, where the BRAF V600E immunohistochemical finding is equivocal or not available.
	☐ CinCSeq Comprehensive Cancer Panel
	☐ FLT3-ITD testing (blood and bone marrow only)
	☐ Pathologic Consult/Second Opinion
PHYSICIAN SIGNATURE	